Alle Storys
Folgen
Keine Story von sanofi-aventis Group mehr verpassen.

sanofi-aventis Group

Sanofi pasteur Supplies Prototype Vaccinefor Italian Government Pandemic Initiatives

Lyon, France (ots/PRNewswire)

- Influenza Vaccine Worldwide Leader sanofi pasteur Contributes to
Italian Influenza Pandemic Preparedness
Sanofi pasteur, the vaccines business of the sanofi-aventis
Group(EURONEXT: SAN; NYSE: SNY), has supplied to the Italian Ministry
of Health a stock of pre-pandemic vaccine against the H5N1 avian
influenza virus strain.Theavian H5N1 strain is one of the candidates
that could lead to a global influenza pandemic, although currently
there is no transmission to and among humans. Under the agreement
with the Italian  Ministry of Health, sanofi pasteur may also provide
pandemic vaccine in the  event of a pandemic being declared, once
theactual virus strain responsible  is identified.
According to the terms of the contract, sanofi pasteur has
supplied,in bulk concentrate form,theH5N1 pre-pandemic vaccine
produced in  its facility in Val de Reuil,France.Formulation and
filling of the vaccine  can be carried out, at any time, at the
request of the Italian Ministry of  Health. If formulated at a
concentration of 15 micrograms of H5N1 antigen per  dose, the stock
delivered is expected to allow the preparation of 185,000  doses of
vaccine.
The contract with the Italian Ministry of Health will be
carriedout in collaboration with Sanofi Pasteur MSD, sanofi pasteur's
joint venture with Merck&Co. Inc. for the development and
distribution of vaccines in Europe; It constitutes yet another step
in sanofi pasteur' s support to theefforts to prepare the world for
the possibility of an influenza pandemic.
- Recently, sanofi pasteur, announced that preliminary results of
clinical trials fielded in France of an adjuvanted candidate H5N1
pre-pandemic influenza vaccine (the one supplied to the Italian
government) demonstrated a good immune response in a significant
number of volunteers. This was the first trial of an H5N1
pre-pandemic influenza vaccine candidate that compared vaccines with
and without adjuvants.
The data will be submitted as part of the company's core "mock up"
vaccine dossier to the European Agency for the Evaluation of
Medicinal Products (EMEA). The core dossier has been developed in
strict accordance to the EMEA guidelines. This process is expected to
reduce the time necessary  for approval of a pandemic vaccine in
Europe once a strain is identified and  a pandemic is declared.
Follow-up studies, currently being planned, will be performed using
vaccine produced at large scale, which will mimic the manufacturing
scale that will be used during adeclared pandemic
  • Sanofi pasteur has entered into an agreement with the French Ministry of Health to produce pre-pandemic vaccine in 2005 in order to create a 1.4 million dose stockpile with the H5N1 candidate studied in the above-mentioned trial. By this agreement, the company could also provide enough vaccine to protect up to 28million people in France in the event of a pandemicbeing declared, once the actual virus strain responsible is identified.
  • Sanofi pasteur has entered into a series of contracts with the US government to increase that country's pandemic preparedness efforts. The contracts include investigational doses for clinical trials; bulk vaccine for stockpiles; establishment and maintenance of laying flocks to enable year-round egg production (not just seasonal), as well as a contract to speed the production process for new cell culture influenza vaccines, including the design of a US-based cell-culture vaccine manufacturing facility.
  • A contract has also been signed with the Australian government for the supply of vaccine in the event of a pandemic influenza outbreak. There are also contacts concerning pandemic preparedness between sanofi pasteur and other governments in Europe and worldwide.
  • Sanofi pasteur is investing in a major expansion of its influenza vaccine production capacity in the US, and also of its vaccine production capacity in France (Val de Reuilfacility).
  • In addition, sanofi pasteur is the only vaccine manufacturer to participate in FLUPAN, an EU-funded collaboration. FLUPAN partners include the National Institute for Biological Standards & Control (NIBSC -UK), the University of Reading (UK), IstitutoSuperiore di Sanita, (Italy),the Health Protection Agency (UK), and the University of Bergen(Norway). FLUPAN is intended to improve the level of pandemic preparedness in the EU. Sanofi pasteur is to produce a vaccine to combat another strain with pandemic potential (H7N1) that will be used in a FLUPAN clinical study.
Influenza Overview
Influenza is a highly contagious virus that is spread easily from
person to person, primarily when an infected individual coughs or
sneezes. An influenza pandemic is a global epidemic of an especially
virulent virus, against which humans have little or no immunity, with
the potential for  severe morbidity and mortality. According to the
World Health Organization  (WHO), the next pandemic is likely to
result in 1 to 2.3 million  hospitalizations and 280,000 to650,000
deaths in industrialized nations  alone. Its impact will most likely
beeven more devastating in developing  countries. These reasons have
lead many countries like Italy to organise  national plans against
influenza pandemic
About sanofi-aventis
The sanofi-aventis Group is the world's third-largest
pharmaceutical  company, ranking number one in Europe. Backed by a
world-class R&D  organization, sanofi-aventis is developing leading
positions in seven major  therapeutic areas: cardiovascular disease,
thrombosis,oncology, metabolic  diseases, central nervous system,
internal medicine, andvaccines. The  sanofi-aventis Group is listed
in Paris(EURONEXT: SAN) and in New York (NYSE:SNY).
Sanofipasteur, the vaccines business of the sanofi-aventis Group,
sold more than abillion doses of vaccine in 2005, making it possible
to protect more than 500 million people across the globe, which is
about 1.5 million per day. The company offers the broadest range of
vaccines, providing protection against 20 bacterial and viral
diseases.For more information,  please visit:www.sanofipasteur.com
Forward Looking Statements
This press release contains forward-looking statements as
definedin the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are statementsthat are not historical
facts. These statements include financial projections and estimates
and their underlying assumptions, statements regarding plans,
objectives and expectations with respect to future operations,
products and services, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expect," "anticipates,""believes," "intends," "estimates," "plans"
and similar expressions.Although sanofi-aventis' management believes
that the expectations reflected in such forward-looking statements
are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond thecontrol of sanofi-aventis, that could cause actual results
and developments to differ materially from those expressed in, or
implied or projected by, theforward-looking information and
statements. These risks and uncertainties include those discussed or
identified inthe public filings with the SEC and the AMF made by
sanofi-aventis, including those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on  Form 20-F forthe year ended
December 31, 2004.Other than as required by  applicable
law,sanofi-aventis does not undertake any obligation to update or
revise any forward-looking information or statements.
Sanofi-aventisGroup subsidiaries in the United States include
Sanofi-Synthelabo Inc., Aventis Pharmaceuticals Inc. and Sanofi
Pasteur Inc.
sanofi pasteur
    Alain BERNAL
    Vice-PresidentCorporate Communications
    Tel:+33-(0)4-37-37-78-97
    Fax:+33-(0)4-37-37-77 89
    sanofi pasteur
    Len LAVENDA
    U.S.Media Relations
    Tel:+1-570-839-4446
     Len.Lavenda@sanofipasteur.com

Contact:

sanofi pasteur: Alain BERNAL, Vice-President Corporate
Communications, Tel:+33-(0)4-37-37-78-97, Fax:+33-(0)4-37-37-77 89.
sanofi pasteur: Len LAVENDA, U.S.Media Relations,
Tel:+1-570-839-4446, Len.Lavenda@sanofipasteur.com

Weitere Storys: sanofi-aventis Group
Weitere Storys: sanofi-aventis Group
  • 21.12.2005 – 07:33

    Sanofi pasteur to License Micro-Delivery Technology From BD Medical

    Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteur's human vaccine products. ...

  • 31.10.2005 – 07:32

    Sanofi Pasteur Announces Agreement to License Novel Adjuvant From Eisai Co., Ltd

    Lyon, France and Swiftwater, Pennsylvania (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has entered into an agreement with Eisai Co., Ltd. to license their novel adjuvant, E6020, for use in the development of new vaccines to treat or prevent human illnesses. E6020 is a chemically synthesized adjuvant that will be ...